I think you'll work on the spending end and it will work out fine. I'm thinking that way too. 55 a share is a nice number and only one application? B has many applications, multiply that factor and it gets dizzying to imagine. Add P and K and it could be beyond staggering. Let's remember the other drug candidates waiting in the wings like the Autism candidate.

If the company achieves their goal of the REGN model, we could easily see multiple triple digit valuations that one could pass on to one's grandkids.

Nice to think of these possibilities but I'm waiting for 10 then 20 and evaluate the company to see where it could go before shedding some shares to complement our lifestyle. Give us an initial partnership with the details for the long term and we'll get a real good roadmap of what future might be.

Can't wait for Biotech in January.